Total Payments
$6,201
2024 Payments
$605.22
Companies
54
Transactions
376
Medicare Patients
2,167
Medicare Billing
$262,695
Payment Breakdown by Category
Food & Beverage$5,978 (96.4%)
Education$222.82 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,978 | 372 | 96.4% |
| Education | $222.82 | 4 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $671.96 | 53 | $0 (2024) |
| PFIZER INC. | $403.18 | 29 | $0 (2023) |
| GENZYME CORPORATION | $388.33 | 21 | $0 (2023) |
| Astellas Pharma US Inc | $368.60 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $329.96 | 23 | $0 (2024) |
| Amgen Inc. | $320.03 | 24 | $0 (2023) |
| Janssen Biotech, Inc. | $301.68 | 15 | $0 (2023) |
| Daiichi Sankyo Inc. | $242.46 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $234.31 | 12 | $0 (2024) |
| Lilly USA, LLC | $228.81 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $605.22 | 22 | Daiichi Sankyo Inc. ($116.77) |
| 2023 | $765.30 | 37 | Merck Sharp & Dohme LLC ($77.83) |
| 2022 | $1,364 | 81 | GENZYME CORPORATION ($161.93) |
| 2021 | $1,356 | 89 | Merck Sharp & Dohme Corporation ($178.74) |
| 2020 | $1,231 | 85 | Merck Sharp & Dohme Corporation ($174.83) |
| 2019 | $838.70 | 59 | PFIZER INC. ($181.75) |
| 2017 | $41.03 | 3 | PFIZER INC. ($41.03) |
All Payment Transactions
376 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Genentech USA, Inc. | Tecentriq (Biological), Tecentriq Hybreza | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: BioOncology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $33.29 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Oncology | ||||||
| 10/21/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: DESMOID TUMORS | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 08/14/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $23.55 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 08/13/2024 | Myriad Genetic Laboratories, Inc. | BRACANALYSIS CDX (Device) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Education | In-kind items and services | $98.99 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $9.93 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/11/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $15.87 | General |
| 03/13/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Oncology | ||||||
| 03/11/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 02/08/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Oncology | ||||||
| 02/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2023 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Rare Disease | ||||||
| 11/15/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: Oncology | ||||||
| 06/29/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 9 | 477 | 3,225 | $132,502 | $34,289 |
| 2021 | 10 | 597 | 4,377 | $155,768 | $53,878 |
| 2020 | 18 | 1,093 | 12,712 | $458,698 | $174,528 |
Total Patients
2,167
Total Services
20,314
Medicare Billing
$262,695
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 96 | 178 | $56,070 | $16,540 | 29.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 80 | 111 | $34,965 | $8,702 | 24.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 116 | 342 | $10,260 | $2,628 | 25.6% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2022 | 15 | 17 | $5,100 | $2,536 | 49.7% |
| 71250 | Ct scan of chest without contrast | Office | 2022 | 17 | 18 | $8,262 | $1,950 | 23.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 114 | 340 | $5,100 | $1,009 | 19.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 14 | 69 | $3,795 | $721.16 | 19.0% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2022 | 14 | 1,700 | $8,500 | $159.39 | 1.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 450 | $450.00 | $41.94 | 9.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 156 | 366 | $73,200 | $32,324 | 44.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 32 | 53 | $13,250 | $4,757 | 35.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 161 | 528 | $15,840 | $4,075 | 25.7% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2021 | 12 | 13 | $7,800 | $3,352 | 43.0% |
| 71270 | Diagnostic ct scan of chest before and after contrast | Office | 2021 | 17 | 20 | $12,000 | $3,200 | 26.7% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 14 | 124 | $8,060 | $3,045 | 37.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 160 | 551 | $8,265 | $1,648 | 19.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 16 | 119 | $5,950 | $1,218 | 20.5% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2021 | 16 | 2,200 | $11,000 | $209.24 | 1.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 13 | 403 | $403.00 | $49.29 | 12.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 15 | 5,880 | $176,400 | $91,986 | 52.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 153 | 235 | $47,000 | $19,607 | 41.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 161 | 243 | $60,750 | $15,019 | 24.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 16 | 80 | $25,600 | $8,235 | 32.2% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2020 | 22 | 24 | $14,400 | $6,431 | 44.7% |
| 71270 | Ct scan chest before and after contrast | Office | 2020 | 27 | 32 | $19,200 | $5,523 | 28.8% |
About Paul Holoye, M. D
Paul Holoye, M. D is a Hematology & Oncology healthcare provider based in Mcallen, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497716401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Paul Holoye, M. D has received a total of $6,201 in payments from pharmaceutical and medical device companies, with $605.22 received in 2024. These payments were reported across 376 transactions from 54 companies. The most common payment nature is "Food and Beverage" ($5,978).
As a Medicare-enrolled provider, Holoye has provided services to 2,167 Medicare beneficiaries, totaling 20,314 services with total Medicare billing of $262,695. Data is available for 3 years (2020–2022), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Mcallen, TX
- Active Since 03/29/2006
- Last Updated 05/30/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1497716401
Products in Payments
- KEYTRUDA (Biological) $611.53
- XTANDI (Drug) $270.78
- Doptelet (Drug) $196.99
- Enhertu (Drug) $191.98
- VERZENIO (Drug) $176.60
- IBRANCE (Drug) $172.61
- MONJUVI (Drug) $154.19
- DARZALEX (Biological) $152.15
- Lenvima (Drug) $147.11
- ENHERTU (Biological) $133.36
- Tavalisse (Drug) $109.89
- XPOVIO (Drug) $107.95
- SOMATULINE DEPOT (Drug) $107.34
- SARCLISA (Biological) $106.24
- Trodelvy (Drug) $103.29
- NERLYNX (Drug) $100.17
- BOSULIF (Drug) $93.86
- KISQALI (Drug) $93.53
- PROMACTA (Drug) $93.19
- Nplate (Biological) $92.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mcallen
Eugenio Galindo, M.d, M.D
Hematology & Oncology — Payments: $23,309
Hematology & Oncology $23,309
Diane Duyen Nguyen, Do, DO
Hematology & Oncology — Payments: $6,872
Hematology & Oncology $6,872
Rodrigo Erana, Md, MD
Hematology & Oncology — Payments: $930.44
Hematology & Oncology $930.44
Dr. Fernando Diaz, Md, MD
Hematology & Oncology — Payments: $61.41
Hematology & Oncology $61.41